Incidental Glioblastoma Tied to Better Outcomes
Glioblastomas can be identified as a result of an incidental MRI finding. A study of 234 patients found four tumors. The study was published as a preprint and has not yet been peer reviewed. First Look
New Investigational Helmet Device Shrinks Glioblastoma
Tumor shrinkage occurred in a patient with end-stage recurrent glioblastoma treated with a novel helmet device that generates a noninvasive oscillating magnetic field. Medscape Medical News
Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMB
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low. Medscape Medical News
Combination Treatment Fails to Improve Survival in Recurrent Glioma
Following tumor resection in patients with recurrent glioblastoma and anaplastic astrocytoma, treatment with vocimagene amiretrorepvec and with flucytosine provides no improvement in overall survival, according to an open-label phase 2/3 trial. Reuters Health Information
Death by 1000 Clicks: Where EHRs Went Wrong
The pain radiated from the top of Annette Monachelli's head, and it got worse when she changed positions. It didn't feel like her usual migraine. The 47-year-old Vermont attorney turned innkeeper visited her local doctor at the Stowe Family Practice twice about the problem in late November 2012, but got little relief.
Two months later,...
PBM Delays for Cancer Drugs May Risk Lives, Warn Oncologists
The patient had metastatic kidney cancer, and his oncologist was seeking to treat him with sunitinib malate (Sutent, Pfizer), a preferred first-line oral therapy. But the patient's pharmacy benefit manager (PBM) refused to cover the cost of the medication. The PBM told the oncologist that the patient's kidney must first be removed.
However, the patient's...
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
Introduction
Hormone receptor (HR)-positive breast cancers (BCs), which represent up to 75% of invasive BCs, are characterised by the presence of receptors for oestrogen (ER) and/or progesterone (PgR). Endocrine therapy (ET) remains the therapeutic backbone for the treatment of HR-positive patients with BC.1 However, up to 50% of HR-positive patients with metastatic breast cancer (MBC)...
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
ESMO/ASCO Global Curriculum Working Group
Chair
Christian Dittrich, MD, Professor of Medicine
Head of 3rd Medical Department—Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria
Members
Emilio Alba Conejo, MD
Director of UGCI Oncology Intercentros, Hospital Universitario Virgen de la Victoria y Regional de Malaga, Malaga, Spain
Rossana Berardi, MD, Professor of Medical Oncology
Head of Department of Medical Oncology, Università...
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Find the Fact Sheet on NTRK/TrkB here: http://oncologypro.esmo.org/Publications/Glossary-of-Molecular-Biology/Glossary-in-Molecular-Biology
Introduction
The treatment of solid tumours is dramatically changing in recent years thanks to the enhancement of molecular diagnostic technologies leading to identification of an increasing number of specific actionable oncogenic abnormalities such as gene activating point mutations, in-frame insertions/deletions and amplification or rearrangements. The concept of precision...
